Frovatriptan Succinate Tablet
Category: Neurology
FDA status: To Be Discontinued · Last FDA update: Nov 12, 2025 · First posted: Feb 24, 2026 · 1 manufacturers, 2 listed presentations
As of Nov 12, 2025, the FDA lists Frovatriptan Succinate Tablet as being discontinued. Of 2 manufacturer presentations, 2 Not specified.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Frova, Tablet, 2.5 mg (NDC 0603-3718-34) NDC 0603-3718-34 |
Endo Pharmaceuticals, Inc. | Not specified | A business decision was made to discontinue manufacture of the drug. |
| Frova, Tablet, 2.5 mg (NDC 63481-025-09) NDC 63481-025-09 |
Endo Pharmaceuticals, Inc. | Not specified | A business decision was made to discontinue manufacture of the drug. |
Related medications in shortage
Other Neurology medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Frovatriptan Succinate Tablet (FDA data as of Nov 12, 2025). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Frovatriptan Succinate Tablet. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/frovatriptan-succinate-tablet.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).